Shanghai Securities News China SecuritiesOn the evening of October 29th, Jiuzhitang...The company announced that it plans to acquire a portion of the equity of Harbin Jixianglong Biotechnology Co., Ltd. for RMB 210 million and increase its capital in Jixianglong by RMB 100 million. After the aforementioned transactions are completed, Jiuzhitang will hold 51.6667% of the equity of Jixianglong, and Jixianglong will be included in its consolidated financial statements.

It is understood that Jixianglong is a company specializing in peptide generic drug raw materials, peptide drug formulations, and innovative drugs.Jixianglong is a national high-tech enterprise specializing in R&D, production, and technical services, possessing core technologies and processes for the large-scale production of peptide APIs. Jixianglong currently holds 10 API production licenses, 1 formulation license, and 1 API pending approval; 8 of its products are included in national centralized procurement. It ranks third in China in the number of peptide API licenses, with atosiban and oxytocin being among the first domestic products to pass consistency evaluation. Smegglutide and telpolide have been registered with the US FDA and USDMF and obtained National Drug Codes (NDCs), and are currently sold in US pharmacies. It has obtained 16 invention patents, including 7 compound patents. Through this transaction, Jiuzhitang can quickly enter the peptide API market, enriching its product categories and improving its industrial chain layout.

Jixianglong is one of the core drafting units of the "Technical Guidelines for Pharmaceutical Research of Chemically Synthesized Peptide Drugs" issued by the National Medical Products Administration (NMPA). Its core technical team has been deeply involved in the field of peptide APIs and formulations for many years, accumulating rich technical reserves and R&D experience, forming a relatively complete technical system and product pipeline, and possessing continuous innovation capabilities. Overall, Jixianglong has systematic advantages in peptide drug R&D, technology transfer, and industrialization, and possesses good growth potential and investment value.

Jiuzhitang is a pharmaceutical company integrating scientific research, production, sales, and health management, possessing traditional Chinese medicine...The company offers a range of products including modern traditional Chinese medicine , biological agents, and health-related products, and continuously conducts research and development on multiple innovative drugs and stem cell drugs. Jixianglong is a national high-tech enterprise specializing in the research, development, production, and technical services of peptide generic drug raw materials, peptide drug formulations, and innovative drugs . Jiuzhitang stated that after the integration, it will fully leverage business synergies in production, sales channels, R&D, and technology to create new business growth points, thereby deepening Jiuzhitang's overall layout in the pharmaceutical field and enhancing its comprehensive competitiveness. Jixianglong will also receive continuous support from the company in management, platform, resources, capital, brand, and sales channels to further its development.

Source: https://finance.eastmoney.com/a/202510303549920471.html